

RAS Mutations that Become Nonfunctional Kinase Activity

Takuma Hayashi^{1,2,3}, Nobuo Yaegashi^{3,4}, Ikuo Konishi^{1,2,3}

¹National Hospital Organization Kyoto Medical Centre, Kyoto, Japan

²Cancer Precision Medicine at Kyoto University School of Medicine, Kyoto, Japan

³The Japan Agency for Medical Research and Development (AMED), Tokyo, Japan

⁴Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Miyagi, Japan

ABSTRACT

The rat sarcoma viral oncogene homolog (RAS) family of closely related oncogenes (KRAS, HRAS, and NRAS) are the most frequently mutated drivers of malignant transformation. RAS family highly associates the epidermal growth factor receptor (EGFR) mainly. EGF selectively binds to EGFR and triggers the receptor to form a dimer that activates RAS. RAS transmits signals from activated trans membrane receptor EGFR to effectors in the B-raf proto-oncogene (BRAF)/mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway in the cytoplasm. The status of RAS proteins is a negative predictive biomarker for anti-EGFR therapy in metastatic colon cancer or other malignant tumors. In here, we report that our clinical studies revealed that splicing caused by the RAS mutations, which were considered oncogenic, generates unfunctional RAS family. Especially, Kirsten Rat Sarcoma (KRAS) silent variants are of concern to be a serious problem in genomic cancer medicine.

The status of rat sarcoma viral oncogene homolog (RAS) proteins is a negative predictive biomarker for anti-epidermal growth factor receptor (EGFR) therapy in metastatic colon cancer. In the phase 2 CHRONOS trial, patients with mutant gene(s) are ineligible for anti-EGFR therapy.^{1,2} However, our studies revealed that splicing caused by the RAS mutations, which were considered oncogenic, generates unfunctional RAS family. Especially, Kirsten Rat Sarcoma (KRAS) silent variants are of concern to be a serious problem in genomic cancer medicine.

The RAS superfamily (Ras protein, RAS subfamily) is a small guanosine triphosphate (GTP)-binding protein that regulates transcription, cell proliferation, and cell motility. Moreover, RAS is a molecule involved in many biological phenomena, such as the suppression of cell death. The RAS gene is a type of protooncogene because RAS mutants are significantly associated with the cancerization and carcinogenesis of cells. Mutations in the *KRAS* gene are the most frequent drivers of tumor development across the spectrum of human cancers.^{3,4} Normally, RAS is inactivated by binding to guanosine diphosphate (GDP). However, when GDP is exchanged for GTP by a guanine nucleotide exchange factor (GEF), RAS is markedly activated in cancer cells. Moreover, when all tyrosine kinase receptors (TKRs), including

platelet-derived growth factor (PDGF), nerve growth factor (NGF), EGF, *etc.*, are stimulated, RAS is constantly activated (Figure 1A).

The most common mechanisms of resistance identified upon rechallenge of panitumumab were mutations or amplifications in the *EGFR*, *KRAS*, and *NRAS* genes, observed in approximately 48% of patients with recurrent colon cancer. Suppose a missense mutation occurs in the RAS amino acid sequence in which G13 and Q61 in the depression to which GTP binds are replaced with another amino acid.^{1,2} In that case, such mutant RAS can bind to GTP, but mutant RAS cannot hydrolyze GTP and are constantly activated. In the phase 2 CHRONOS trial, as expected, *KRAS* and *NRAS* mutations occurred frequently at position 61.^{3,4} Therefore, mutations that

How to cite this paper: Takuma Hayashi | Nobuo Yaegashi | Ikuo Konishi "RAS Mutations that Become Nonfunctional Kinase Activity" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-6 | Issue-7, December 2022, pp.457-460, URL: www.ijtsrd.com/papers/ijtsrd52365.pdf



Copyright © 2022 by author (s) and International Journal of Trend in Scientific Research and Development Journal. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (<http://creativecommons.org/licenses/by/4.0>)



KEYWORDS: *KRAS*, *oncogenic variant*, *Cancer Genome Medicine*, *EGFR*

are constitutively activated and result in oncogeneization are called oncogenic or pathogenic mutations.

The two antitumor agents covered by insurance as molecular-targeted therapies for colorectal cancer are bevacizumab, an anti-vascular endothelial growth factor (VEGF) agent, and cetuximab and panitumumab, which are anti-EGFR antibody agents (Figure 1A).⁵ Approximately forty percent of patients with colon cancer have the pathogenic *KRAS* gene mutation(s), which leads to runaway cell proliferation and the rapid growth of cancer cells even without the EGF signal. In the case of colorectal cancer cells with the mutant *KRAS* gene, the response of molecular-targeted drugs to EGFR is not observed.⁶ Therefore, the RAS status is a negative predictive biomarker for anti-EGFR therapy in metastatic colon cancer,⁷ and identification of the *KRAS* gene mutations by genetic testing such as the oncoBEAM™ RAS CRC kit is essential before anti-EGFR treatment.

Kobayashi *et al.* elucidated that RAS Q61K mutation caused a change in the generation (splicing) of *RAS* mRNA, such that the mature mRNA—and thus the protein—was truncated and nonfunctional (Figure 1B).⁸ However, in the case of a RAS Q61K mutation in which the codon of 60G has (GGA, GGC, GGG), splicing does not occur, so the RAS Q61K is oncogenic functional.⁸

The recent report states that although oligonucleotide drug technology is advancing rapidly, the therapeutic use of oligonucleotides for suppressing oncogenic *KRAS* signaling remains theoretical.⁹ Recent report also shows that the development of small-molecule-specific inhibitors of splicing in exon 3 of *RAS* oncogenes is a candidate strategy for the growing portfolio of approaches that are being pursued to target cancers with oncogenic RAS; unfortunately the clinical applications of this work may be distant.⁷

From December 2019 to August 2022, a total of 2016 cases (OncoGuide™ NCC Oncopanel System* test: 302 cases, Foundation One[®] CDx** tissue test: 1567 cases, Foundation One[®] CDx liquid test: 147 cases) were investigated in cancer genomic medicine at a national university in Japan. Recently, our medical team examined total 325 patients with recurrent colon cancer in cancer genomic medicine, and then our medical team obtained the reports indicating detection result of *KRAS* Q61K, *KRAS* Q61L, and *KRAS* Q61H as oncogenic variants (also called druggable variant or pathogenic variant)*** in cancer genomic medicine by Foundation One[®] CDx for total 5 patients with recurrent colon cancer (Table 1). By retesting with ClinVar and OncoKB, *KRAS* Q61K,

KRAS Q61L and *KRAS* Q61H were pathogenic variants. Therefore, our medical staff has abandoned the prescription of anti-EGFR inhibitors for recurrent colon cancer. However, after confirming the contents of the research by Kobayashi *et al.*⁸, our medical team revealed by using whole DNA/RNA gene sequence analysis and Entrez Gene program that *KRAS* Q61K, *KRAS* Q61L, *KRAS* Q61H, and *KRAS* Q61R were *KRAS* GGT (G60), AAA (K61), CTA (L61), CAT (H61), and CGA (R61) in short, these *KRAS* variants were nonfunctional *KRAS* caused by altered splicing from the cryptic splice donor site (Table 1). The response of panitumumab, an anti-EGFR inhibitor, has been confirmed for patients with colon cancer. Notably, the findings obtained from the research conducted by Kobayashi *et al.*⁸ have already brought great benefits to the lives of cancer patients with recurrent colon cancer in clinical practice.

Currently, personalized medical care for patients with malignant tumors is being performed based on the results of cancer genome tests. As shown in the phase 2 CHRONOS trial, in the future treatment of recurrent colon cancer, liquid biopsies should prospectively be used to define treatment choice with an anti-EGFR antibody in patients with recurrent colon cancer. The results obtained from Foundation One[®] CDx tissue, Foundation One[®] CDx liquid, and other molecular tests to detect the variants (i.e., mutations, high copy number of gene, loss of gene, *etc.*) are considered oncogenic, benign or variants of unknown significance (VUS) using updated databases including ClinVar, ConcoKB, cosmic, VarSome, and MGenD. However, the database used for cancer genomic testing, as in the case of *KRAS* this time, is not constantly updated. In the future, the contents of the genome-wide databases must be updated based on the results obtained from basic medical and clinical research.

Footnote

OncoGuide™ NCC oncopanel System*; Gene mutation analysis set for cancer genome profiling test (Sysmex Corporation Kobe, Hyogo, Japan)

FoundationOne CDx**; cancer genome test (Foundation Medicine, Inc., Cambridge MA, USA)

Oncogenic variants (also called as druggable variants or pathogenic variant)***; These variants include oncogenic/pathogenic mutations, high-expression/high copy number, and gene loss.

Author Contributions: T.H. performed most of the clinical work and coordinated the project. T.H. conducted the diagnostic pathological studies. T.H. conceptualized the study and wrote the manuscript. T.H., N.Y. and I.K. carefully reviewed this

manuscript and commented on the aspects of medical science. I.K. shared information on clinical medicine and oversaw the entirety of the study. All authors have read and agreed to the published version of the manuscript.

Funding: This clinical research was performed with research funding from the following: Japan Society for Promoting Science for TH (Grant No. 19K09840), START-program Japan Science and Technology Agency for TH (Grant No. STSC20001), and the National Hospital Organization Multicenter clinical study for TH (Grant No. 2019-Cancer in general-02).

Institutional Review Board Statement: This study was reviewed and approved by the Central Ethics Review Board of the National Hospital Organization Headquarters in Japan (Tokyo, Japan) and Shinshu University (Nagano, Japan) on August 17, 2019, with approval codes NHO H31-02 and M192. The completion numbers for the authors are AP0000151756, AP0000151757, AP0000151769, and AP000351128. As this research was considered clinical research, consent to participate was required. After briefing regarding the clinical study and approval of the research contents, the participants signed an informed consent form.

Informed Consent Statement: Not applicable for studies not involving humans.

Data Availability Statement: The study did not report any data.

Acknowledgments: We appreciate Dr. Weinberg RA (M.I.T., MA, USA.) and Dr. Zhang W (Roche Tissue Diagnostics, Tucson, AZ, USA.) for critical

comments. We thank all medical staff for clinical research at Kyoto University School of Medicine and the National Hospital Organization Kyoto Medical Center. We appreciate Crimson Interactive Japan Co., Ltd., for revising and polishing our manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

Reference

- [1] Sartore-Bianchi A, et al. *Nat Med.* Aug; 28(8):1612-1618 (2022). doi:10.1038/s41591-022-01886-0.
- [2] Sidaway P. *Nature Reviews Clinical Oncology.* Aug 25 (2022). doi:10.1038/s41571-022-00681-7.
- [3] Sanchez-Vega F, et al. *Cell.* Apr 5; 173(2):321-337.e10. (2018) doi:10.1016/j.cell.2018.03.035.
- [4] Herbst RS, Schlessinger J. *Nature.* Nov; 575(7782):294-295 (2019). doi:10.1038/d41586-019-03242-8.
- [5] Ottaiano A, et al. *Front Pharmacol.* May 3; 9: 441 (2018) doi: 10.3389/fphar.2018.00441.
- [6] Goel S, et al. *Curr Clin Pharmacol.* 10(1): 73-81 (2015) doi:10.2174/1574884708666131111204440.
- [7] Kim TW, et al. *Clin Colorectal Cancer.* Sep; 17(3):206-214 (2018) doi:10.1016/j.clcc.2018.03.008.
- [8] Kobayashi Y, et al. *Nature* 603:335-342 (2022).
- [9] Molina-Arcas M, Downward J. *N Engl J Med* 386:2523-2525 (2022).

Figure 1. Identification of nonfunctional KRAS Q61K variant of patient with recurrent colon cancer by using whole gene sequence analysis. A. An overview of the EGFR pathway and its main downstream effectors, KRAS/BRAF/MEK/ERK. Notes: Activated MEK/ERK can induce cancer cell proliferation and invasion. Anti-EGFR mAbs, such as cetuximab or panitumumab, can bind EGFR and block its function. **B.** Recent research demonstrated that the oncogenic effect of an activating variant (the KRAS Q61K mutation) was dependent on a second, silent variant, G60, in KRAS. The mutation resulting in KRAS Q61K produces aberrant RNA splicing in exon 3, which results in a frameshift (in exon 4) and the introduction of an early stop codon. Abbreviations: BRAF; B-raf protooncogene, EGFR; epidermal growth factor receptor, ERK; extracellular signal-regulated kinase, KRAS; Kirsten murine sarcoma, MEK; mitogen-activated protein kinase

Table 1. KRAS Q61K was determined to be an oncogenic variant in genomic cancer medicine by Foundation One[®] CDx for a patient with recurrent colon cancer. By retesting with ClinVar, KRAS Q61K was a pathogenic variant. The studies by using whole gene sequence analysis and Entrez Gene program revealed that KRAS Q61K, KRAS Q61L, KRAS Q61H, and KRAS Q61R were KRAS GGT (G60) and AAA (K61), CTA (L61), CAT (H61), and CGA (R61) and was nonfunctional KRAS caused by altered splicing from the cryptic splice donor site.




Figure 1

Cases of patients with recurrent colon cancer

| Results of Foundation One CDx for KRAS mutations | | | | | | |
|---|---------------|---------------|------------------|-------------------|-----------------|-------------------|
| KRAS | Amino Acid | | F1CDx | ClinVar | KRAS Activation | Anti-EGFR therapy |
| Wild Type | G60 | Q61 | - | - | normal | Response |
| Patient #1 | G60 | K61 | oncogenic | pathogenic | functional | Resistance |
| Patient #2 | G60 | L61 | oncogenic | pathogenic | functional | Resistance |
| Patient #3 | G60 | H61 | oncogenic | pathogenic | functional | Resistance |
| Patient #4 | G60 | H61 | oncogenic | pathogenic | functional | Resistance |
| Patient #5 | G60 | L61 | oncogenic | pathogenic | functional | Resistance |
| Patient #6 | G60 | R61 | oncogenic | pathogenic | functional | Resistance |
| Results of genome DNA/RNA sequence analysis and Entrez Gene program | | | | | | |
| | codon of aa60 | codon of aa61 | RNA function | KRAS Activation | | |
| Wild Type | GGT (G60) | CAA (Q61) | normal function | Normal activation | | Response |
| Patient #1 | GGT (G60) | AAA (K61) | altered splicing | nonfunctional | | Response |
| Patient #2 | GGT (G60) | CTA (L61) | altered splicing | nonfunctional | | Response |
| Patient #3 | GGT (G60) | CAT (H61) | altered splicing | nonfunctional | | Response |
| Patient #4 | GGT (G60) | CAT (H61) | altered splicing | nonfunctional | | Response |
| Patient #5 | GGT (G60) | CTA (L61) | altered splicing | nonfunctional | | Response |
| Patient #6 | GGT (G60) | CGA (R61) | altered splicing | nonfunctional | | Response |

Table 1